Five Themes Likely to Emerge at ECO2026 in Istanbul

Key Takeaways

• Obesity research shifting focus from weight loss to metabolic health outcomes
• Next-gen therapies include amylin agents, oral GLP‑1s, and muscle‑preserving combos
• Obesity framed as gateway disease driving cancers and other conditions
• Precision medicine approaches target ethnicity, body composition, and treatment heterogeneity
• Systems thinking promotes coordinated policy, clinical, and societal actions against obesity

Pulse Analysis

ECO2026 marks a watershed moment for the obesity field, reflecting a transition from simple scale‑centric metrics to a holistic view of health. Attendees will hear data linking excess adiposity to cardiovascular disease, sleep apnea, liver dysfunction, and functional decline, underscoring the need for interventions that improve long‑term outcomes. This shift aligns with payer demands for value‑based care and positions pharmaceutical firms to demonstrate broader clinical benefits beyond weight reduction.

The congress also spotlights a new wave of therapeutics poised to reshape treatment algorithms. While semaglutide and tirzepatide remain benchmarks, emerging candidates—amylin analogues, oral GLP‑1 formulations, and combination regimens like CagriSema—promise greater durability, tolerability, and muscle preservation. Researchers are probing these agents not only for deeper weight loss but for their capacity to mitigate downstream complications such as obesity‑related cancers, a concept that is moving from speculation to trial design.

Beyond drugs, the dialogue is increasingly personalized and systemic. Precision medicine discussions explore how ethnicity, body composition, and genetic heterogeneity dictate response, urging clinicians to move beyond BMI thresholds. Simultaneously, a systems‑thinking framework calls for coordinated policy, clinical pathways, and societal interventions to address stigma, inequity, and environmental drivers. Companies that embed these insights into product development, market access, and advocacy will be better positioned to lead in a landscape where obesity is treated as an adiposity‑based chronic disease rather than a lifestyle choice.